세계의 자궁내막증 시장 보고서(2025년)
Endometriosis Global Market Report 2025
상품코드 : 1824658
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 자궁내막증 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년까지 CAGR 9.4%로 확대되어 22억 1,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 저침습 수술, 의약 혁신, 유전자 및 후성 연구, 여성 건강 관리의 세계적 확장에 기인합니다. 예측기간의 주요 동향으로는 환자 중심 케어, 정밀의료, 가상 케어와 원격 의료, 임신성 온존 등이 있습니다.

향후 5년간의 성장률 9.4%라는 예측은 지난 예측으로부터 0.1% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 상승은 프랑스와 벨기에에서 조달하는 복강경 절제기구와 호르몬 요법의 비용을 높여 자기 부담액을 악화시키고 저침습 수술을 지연시킴으로써 미국 환자에게 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.

난소암의 유병률 증가는 자궁내막증 시장의 예상 성장의 원동력이 될 것으로 예측됩니다. 난소암은 난소(난자의 생산과 호르몬 분비를 담당하는 중요한 여성의 생식기관)에서 발생하는 악성 종양으로 자궁내막증과 본질적으로 관련되어 있습니다. 이 상태는 특정 난소암 아형, 특히 에스트로겐농도의 상승을 특징으로 하는 자궁내막암 아형과 정밀세포암 아형의 개발 리스크를 높여 난소암 리스크를 상승시키고 있습니다. 예를 들어, 2023년 1월 미국암 협회의 데이터에서 2023년 미국 여성 난소암의 신규 증례는 약 1만 9,710례로 예측됐습니다. 또한 미국에 본사를 둔 비영리 단체인 Ovarian Cancer Research Alliance는 2022년 난소암 관련 사망자 수를 1만 2,810명으로 보고하고, 2023년에는 1만 3,270명으로 증가할 것으로 예측했습니다. 그 결과, 난소암 이환율의 급증이 자궁내막증 시장 확대의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Endometriosis is a chronic medical condition characterized by the growth of tissue similar to the uterine lining (endometrium) outside the uterus. This condition often results in severe pelvic pain and can complicate fertility, significantly impacting an individual's overall well-being and ability to conceive.

Endometriosis presents in various forms, including superficial peritoneal lesions, endometrioma, deeply infiltrating endometriosis, and other less common manifestations. Superficial peritoneal lesions denote a specific type of abnormal tissue growth associated with endometriosis and typically necessitate treatments like hormonal therapy and pain management. Several drugs and therapies are available for managing this condition, including oral contraceptives, progestins, nonsteroidal anti-inflammatory drugs (NSAIDs), GnRH analogs, levonorgestrel-releasing intrauterine devices (LNR-IUDs), among others. These treatments are administered by different healthcare end-users, such as hospitals, homecare services, specialty centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The endometriosis market research report is one of a series of new reports from The Business Research Company that provides endometriosis market statistics, including endometriosis industry global market size, regional shares, competitors with an endometriosis market share, detailed endometriosis market segments, market trends and opportunities and any further data you may need to thrive in the endometriosis industry. This endometriosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endometriosis market size has grown strongly in recent years. It will grow from $1.4 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to delayed diagnosis and increased awareness, advances in laparoscopic surgery, hormonal therapies, patient advocacy and support groups.

The endometriosis market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to minimally invasive procedures, pharmaceutical innovations, genetic and epigenetic research, global expansion of women's healthcare. Major trends in the forecast period include patient-centered care, precision medicine, virtual care and telemedicine, fertility preservation.

The forecast of 9.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of laparoscopic excision tools and hormonal therapies sourced from France and Belgium, exacerbating out-of-pocket expenses and delaying minimally invasive surgeries. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The escalating prevalence of ovarian cancer is poised to be a driving force behind the anticipated growth of the endometriosis market. Ovarian cancer, a malignancy originating in the ovaries - vital female reproductive organs responsible for egg production and hormone secretion - is intrinsically linked to endometriosis. This condition heightens the risk of developing certain ovarian cancer subtypes, notably the endometrioid and precise cell cancer subtypes characterized by elevated estrogen concentrations, which can elevate ovarian cancer risk. As an illustration, data from the American Cancer Society in January 2023 projects around 19,710 new cases of ovarian cancer among women in the United States for 2023. Additionally, the Ovarian Cancer Research Alliance, a U.S.-based not-for-profit organization, reported 12,810 ovarian cancer-related fatalities in 2022, with a rise to 13,270 expected in 2023. Consequently, the surge in ovarian cancer incidence is a driving factor behind the expansion of the endometriosis market.

The upswing in government funding is anticipated to propel the growth of the endometriosis market. Government funding encompasses financial support provided to non-government entities, wherein all or a portion of the financial backing is supplied by government entities. Typically channeled through grants and contracts, government funding is instrumental in advancing endometriosis research, benefitting individual researchers and research institutions conducting clinical studies. As an example, in March 2022, the U.S. federal government unveiled a commitment of $92 million in funding for the National Institute of Child Health and Human Development (NICHD). The Department of Defense's Peer-Reviewed Medical Research Programme (PRMRP) continues to receive substantial support with $370 million in funding for endometriosis research. Consequently, the upsurge in government funding plays a pivotal role in propelling the growth of the endometriosis market.

Prominent companies engaged in the endometriosis market are placing their focus on the development of innovative medications, including Myfembree, and securing approvals to introduce fresh treatment options for patients. The advent of novel medications for endometriosis addresses a previously unmet need for effective treatments. For instance, in August 2022, Myovant Sciences GmbH, a Switzerland-based biopharmaceutical company, in collaboration with Pfizer Inc., a U.S.-based pharmaceutical industry company, secured approval from the U.S. Food and Drug Administration (FDA) for Myfembree. This medication is designed for the management of moderate to severe pain associated with endometriosis in premenopausal women. Myfembree is a once-daily pill that combines three vital components such as relugolix, estradiol, and norethindrone acetate, offering proven relief to premenopausal women with two indications in a single pill. This presents an alternative treatment choice for women who cannot or prefer not to use hormone therapy.

In February 2022, Theramex, a U.K.-based pharmaceutical company specializing in women's health, particularly in contraception, fertility, menopause, and osteoporosis, entered a partnership with ObsEva SA. The collaboration aims to commercialize Linzagolix, an oral GnRH antagonist, for women experiencing uterine fibroids and endometriosis-related pain, with potential royalties reaching up to USD 80.03 million (EUR 72.75 million). ObsEva SA, a Switzerland-based biopharmaceutical company, focuses on developing and commercializing innovative therapies for women's reproductive health and pregnancy.

Major companies operating in the endometriosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., Abbvie Inc., Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Ipsen Pharma Biotech S.A.S., Cadila Pharmaceuticals Ltd., Gedeon Richter PLC, Torrent Pharmaceuticals Ltd., Neurocrine Biosciences Inc., Ferring Pharmaceuticals, Prestige Consumer Healthcare Inc., Almirall S.A, Evotec BioSystems GmbH, Serum Institute of India Pvt. Ltd., Kissei Pharmaceutical Co. Ltd., Sanofi India Ltd., DebioPharm Group, Repros Therapeutics Inc., Meditrina Pharmaceuticals Private Limited, Zenomed Healthcare Private Limited.

North America was the largest region in the endometriosis market in 2024. The regions covered in endometriosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the endometriosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endometriosis market consists of revenues earned by entities by providing services such as laparoscopy, nutritional counseling, physical therapy, diagnostic laparoscopy, fertility treatment, surgical interventions and complementary therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The endometriosis market also includes sales of birth control pills, patches and vaginal rings. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Endometriosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on endometriosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for endometriosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The endometriosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Endometriosis Market Characteristics

3. Endometriosis Market Trends And Strategies

4. Endometriosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Endometriosis Growth Analysis And Strategic Analysis Framework

6. Endometriosis Market Segmentation

7. Endometriosis Market Regional And Country Analysis

8. Asia-Pacific Endometriosis Market

9. China Endometriosis Market

10. India Endometriosis Market

11. Japan Endometriosis Market

12. Australia Endometriosis Market

13. Indonesia Endometriosis Market

14. South Korea Endometriosis Market

15. Western Europe Endometriosis Market

16. UK Endometriosis Market

17. Germany Endometriosis Market

18. France Endometriosis Market

19. Italy Endometriosis Market

20. Spain Endometriosis Market

21. Eastern Europe Endometriosis Market

22. Russia Endometriosis Market

23. North America Endometriosis Market

24. USA Endometriosis Market

25. Canada Endometriosis Market

26. South America Endometriosis Market

27. Brazil Endometriosis Market

28. Middle East Endometriosis Market

29. Africa Endometriosis Market

30. Endometriosis Market Competitive Landscape And Company Profiles

31. Endometriosis Market Other Major And Innovative Companies

32. Global Endometriosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Endometriosis Market

34. Recent Developments In The Endometriosis Market

35. Endometriosis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기